R
Rakesh K. Jain
Researcher at Harvard University
Publications - 1528
Citations - 198912
Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.
Papers
More filters
Journal ArticleDOI
Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?
TL;DR: It is proposed that, whereas active intravasation of cells into the circulation is important in some tumours, others might shed cells passively into the blood or lymphatic vessels without the involvement of active cell migration.
Journal Article
Interstitial Hypertension in Head and Neck Tumors in Patients: Correlation with Tumor Size
R. Gutmann,Michael Leunig,J. Feyh,Alwin E. Goetz,Konrad Messmer,E. Kastenbauer,Rakesh K. Jain +6 more
TL;DR: The value of IFP as a predictor of response to radiotherapy, photodynamic therapy, hyperthermia, and chemotherapy should be assessed prospectively.
Journal ArticleDOI
Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.
Ivy X. Chen,Vikash P. Chauhan,Vikash P. Chauhan,Jessica M. Posada,Jessica M. Posada,Mei Rosa Ng,Michelle W. Wu,Pichet Adstamongkonkul,Peigen Huang,Neal I. Lindeman,Robert Langer,Rakesh K. Jain +11 more
TL;DR: It is shown that targeting CXCR4/CXCL12 signaling, using plerixafor, an Food and Drug Administration-approved drug, reduces fibrosis, alleviates immunosuppression, and significantly enhances the efficacy of immune checkpoint blockers in preclinical models of mBC.
Journal ArticleDOI
Tumor Blood Flow-Characterization, Modifications, and Role in Hyperthermia
TL;DR: The objective of this paper is to summarize the data on tumor blood flow rate during normothermia and hyperthermia, and to discuss the use of pharmacological agents in modifying the tumorBlood flow rate for therapeutic benefits.
Journal ArticleDOI
Vascular permeability in a human tumour xenograft: molecular charge dependence.
TL;DR: The results indicate that positively charged molecules extravasate faster in solid tumours compared to the similar-sized compounds with neutral or negative charges, indicating that the modification of proteins enhances drug delivery to normal organs as well.